KOREA PHARMA acquires 18 billion won worth of convertible bonds before maturity, reducing potential dilution risk and improving financial structure
Bond acquisition overview: KOREA PHARMA acquired 18 billion won of its 4th series unsecured private convertible bonds (face value 18 billion won, conversion price 21,862 won) before maturity and plans to cancel them. After acquisition, remaining balance is 5 billion won.
Reason for acquisition: The company purchased the bonds due to the bondholders' exercise of early redemption rights. The bonds will be canceled through the Korea Securities Depository.
Funding source and scale: The acquisition used 18 billion won of the company's own funds, equivalent to 16.4% of its current market cap (approx. 109.4 billion won), which may pressure cash liquidity.
Impact on shareholders: Cancellation of the convertible bonds reduces potential dilution risk and improves the financial structure by lowering debt. Although conversion was unlikely given the current stock price (10,030 won) far below the conversion price (21,862 won), the remaining 5 billion won in bonds still poses a burden.
[AI Comprehensive Analysis]KOREA PHARMA's early redemption of convertible bonds using its own funds is positive for financial health, but the large cash outlay raises concerns about liquidity reduction. The remaining 5 billion won in convertible bonds remains a burden, and further financial measures may be needed if the stock price remains weak.
KOSDAQ Filing Information
Filing: Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) Before Maturity After Issuance